What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Antibiotics
- Surgery
Vancomycin, Antibacterial agent, Staphylococcus aureus, Microbiology and Daptomycin are his primary areas of study.
His research in Vancomycin intersects with topics in Infective endocarditis, Surgery, Internal medicine and Minimum inhibitory concentration.
His Antibacterial agent study is concerned with the field of Antibiotics as a whole.
His Staphylococcus aureus research is multidisciplinary, incorporating elements of Glycopeptide and Pharmacology.
His Microbiology research is multidisciplinary, relying on both Pseudomonas aeruginosa and SCCmec.
His work carried out in the field of Daptomycin brings together such families of science as Nafcillin, Enterococcus faecium, Vancomycin-resistant Staphylococcus aureus, Gram-positive bacteria and Gentamicin.
His most cited work include:
- Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children (2524 citations)
- Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. (1246 citations)
- Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association (1175 citations)
What are the main themes of his work throughout his whole career to date?
Michael J. Rybak focuses on Microbiology, Vancomycin, Staphylococcus aureus, Daptomycin and Antibiotics.
Michael J. Rybak works mostly in the field of Microbiology, limiting it down to topics relating to Pharmacology and, in certain cases, Levofloxacin, as a part of the same area of interest.
Michael J. Rybak has researched Vancomycin in several fields, including Glycopeptide, Internal medicine, Staphylococcal infections and Methicillin-resistant Staphylococcus aureus.
His Internal medicine research incorporates themes from Bacteremia and Surgery.
His work is dedicated to discovering how Staphylococcus aureus, Endocarditis are connected with Infective endocarditis and other disciplines.
In his work, Enterococcus faecalis is strongly intertwined with Enterococcus faecium, which is a subfield of Daptomycin.
He most often published in these fields:
- Microbiology (105.60%)
- Vancomycin (90.80%)
- Staphylococcus aureus (71.70%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (53.74%)
- Vancomycin (90.80%)
- Microbiology (105.60%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Vancomycin, Microbiology, Methicillin-resistant Staphylococcus aureus and Daptomycin.
His Internal medicine study which covers Bacteremia that intersects with Ceftazidime/avibactam, Carbapenem-resistant enterobacteriaceae, Medical microbiology and Ceftaroline fosamil.
Vancomycin is a primary field of his research addressed under Staphylococcus aureus.
His work deals with themes such as Pseudomonas aeruginosa, Acinetobacter baumannii and Endocarditis, which intersect with Microbiology.
His Methicillin-resistant Staphylococcus aureus research focuses on Cefepime and how it connects with Concomitant.
His Daptomycin study combines topics from a wide range of disciplines, such as Enterococcus faecium, Dalbavancin, Pharmacodynamics, Combination therapy and Ceftriaxone.
Between 2018 and 2021, his most popular works were:
- Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. (25 citations)
- Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. (25 citations)
- Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint (23 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Antibiotics
- Surgery
Michael J. Rybak spends much of his time researching Internal medicine, Bacteremia, Antibiotics, Methicillin-resistant Staphylococcus aureus and Microbiology.
His Internal medicine research is multidisciplinary, relying on both Carbapenem-resistant enterobacteriaceae and Multiple drug resistance.
His studies deal with areas such as Daptomycin and Retrospective cohort study as well as Bacteremia.
His work in Methicillin-resistant Staphylococcus aureus tackles topics such as Vancomycin which are related to areas like Concomitant, Cefepime and Hazard ratio.
His Microbiology research is multidisciplinary, incorporating perspectives in Pseudomonas aeruginosa, Bacteriophage, Klebsiella pneumoniae and Staphylococcus aureus.
His studies in Staphylococcus aureus integrate themes in fields like Glycopeptide and PK/PD models.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
